<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 10 Mar 2021 07:32:55 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>人人学懂免疫学：第一期</title><link>https://mp.weixin.qq.com/s/NkdSC4n4VV-rKH84hDTdJA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/DHzmPyEdSc2q4Vv79kusG4MXq01qibic2TCRqkCed2V0LF3HhGuiaHotSB0RXa81eBfBXkY4zN8wnr1FMzSGic6d6Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>免疫(immunity)这个词来源于罗马时代的拉丁文“immunis”，其原意为“免除税收”]]></content:encoded><pubDate>Wed, 10 Mar 2021 06:20:33 +0800</pubDate></item><item><title>人人学懂免疫学：第二期</title><link>https://mp.weixin.qq.com/s/-Bkafg8Ifg9-kYfs9DcZzw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/DHzmPyEdSc1eZ1Kw1UJjdj7QWPhSF4GM2okV07vhcJcCc9RQw3RKXGViccbB3rwRbzqibzPl1kzxPTRESrWicb96A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>固有免疫系统的防御策略]]></content:encoded><pubDate>Wed, 10 Mar 2021 06:20:33 +0800</pubDate></item><item><title>人人学懂免疫学：第三期</title><link>https://mp.weixin.qq.com/s/mNj53Pc0wsXASqc_1SnuIg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/DHzmPyEdSc3VYoH2FdjMjTaPribmI2NOS9RMyhzNmNgFibsdj3oOYa0TR2M4O8DLYwuffSyEMrPcDeBiaoiaicmlyoQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>杀伤性T细胞]]></content:encoded><pubDate>Wed, 10 Mar 2021 06:20:33 +0800</pubDate></item><item><title>人人学懂免疫学：第四期</title><link>https://mp.weixin.qq.com/s/izp4wHV95s4ywF7RbAyUJw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/DHzmPyEdSc3QTEVaJkED9ojaMsRKoHuGepv2BO5CoSHzsqtdzgibuib6OONg5GjsfeQ7do98PFpwO3nxuu9dPtZQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>固有免疫系统]]></content:encoded><pubDate>Wed, 10 Mar 2021 06:20:33 +0800</pubDate></item><item><title>人人学懂免疫学：第五期</title><link>https://mp.weixin.qq.com/s/ClkULIXvInQKp2sfHln8Vg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/DHzmPyEdSc1fzJ3vkIG1qxh3VViaSPXW4DChKNEujiaxlJTpoiamZmxEiadKTLCGDNscXibibRwqEPgdbwHNeR4bcfzw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>凝集素激活途径]]></content:encoded><pubDate>Wed, 10 Mar 2021 06:20:33 +0800</pubDate></item><item><title>小药谈ADC：第三代ADC</title><link>https://mp.weixin.qq.com/s/W0OuHVyA1Q23W0SMzHZpzw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQjPlcE3N9xAGYm8SWPz1gNrOiaOlQK2Rrv0Qzmpx1M7k7CXmFcVQHEicGib9rLBTvONxchZkOolp5Bw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>冲破层层迷障，第三代ADC已崭露头角]]></content:encoded><pubDate>Tue, 09 Mar 2021 06:06:38 +0800</pubDate></item><item><title>小药谈ADC: ADC的盛世华年</title><link>https://mp.weixin.qq.com/s/r1zWNcrTuTBN_CSaq2jmgA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSBpaF4zJROleroo5bWkTibxMEHS97jvVMXN976qb8B1G4adHBPMrt8eWw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>资本与技术共舞，ADC迎来盛世华年]]></content:encoded><pubDate>Tue, 09 Mar 2021 06:06:38 +0800</pubDate></item><item><title>小药谈ADC：ADC的免疫原性</title><link>https://mp.weixin.qq.com/s/wbRHkqAt6bsp7SKWAWw26A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSBGXCHjWibqws9BibNGRXO4xboqImmQhe8CEWQvzalkY1gnib5HuGjYFQ4Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>在11个临床试验的广泛的肿瘤适应症中，8个vc-MMAE-ADC的ADAs发生率在0-35.8%之间。]]></content:encoded><pubDate>Tue, 09 Mar 2021 06:06:38 +0800</pubDate></item><item><title>小药综述：精准医学的关键差距与机遇</title><link>https://mp.weixin.qq.com/s/j-8LnDLGNCBbwbX7tgjXpw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSBvIp4xCs3jNQia5LzXic8fSsqbb9px7Aicm3cu7icTj1wg2EQRGsBgAGYlg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>癌症研究蓝图]]></content:encoded><pubDate>Mon, 08 Mar 2021 06:11:07 +0800</pubDate></item><item><title>小药综述：肿瘤免疫治疗当前的趋势转变</title><link>https://mp.weixin.qq.com/s/M_vNa-kVZO7_9w9HGFDe5Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSBOF9HOFGdo5ibJZFMYcwN4WOXzB73tu59CMeXo0e5vV9gTUibQjwTrTpg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>下一代肿瘤免疫药物的发展方向到底在哪里？]]></content:encoded><pubDate>Mon, 08 Mar 2021 06:11:07 +0800</pubDate></item><item><title>小药综述：靶向抗癌药物的免疫调节作用</title><link>https://mp.weixin.qq.com/s/8DyfqLtKcqpc74SO7S_jOA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSB5dsfHqyEI6SStPY1nvJbTFSHQRzBxyNL5ibDgPjDTHsA3zlib6lVmz5g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>大量的临床前和临床资料表明，几乎所有靶向抗癌药物都或多或少地发挥了免疫刺激或免疫抑制作用。]]></content:encoded><pubDate>Mon, 08 Mar 2021 06:11:07 +0800</pubDate></item><item><title>小药综述：肿瘤代谢重编程与免疫应答</title><link>https://mp.weixin.qq.com/s/3qN64IamxAAmQpNDH4qG3g</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSBQWLhbZlAiakkxic18Icd3gmIHoX2S0cjlibaqcu1DoAv9oZsLfbvHvmXQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>肿瘤和免疫细胞的代谢重编程之间的影响是肿瘤免疫应答公认的的决定因素之一。]]></content:encoded><pubDate>Mon, 08 Mar 2021 06:11:07 +0800</pubDate></item><item><title>小药综述：自身免疫疾病</title><link>https://mp.weixin.qq.com/s/tCKwx59RWdCN1VdB8JsnDw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSBumgQCyDxHeLiaHqcUd6VZDnRFB9dZJ7Nad5oYiaWz2kMmBdcvrqiaQgIQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>自身免疫与炎症性疾病生物疗法三十年来的经验总结。]]></content:encoded><pubDate>Mon, 08 Mar 2021 06:11:07 +0800</pubDate></item><item><title>小药综述：人工智能与药物研发</title><link>https://mp.weixin.qq.com/s/RWgtYRIcnhdoXCIWZNwopw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSBice1Hh71zkQ5t0ibuiboMXlH0cCAa6WicJBayaFQSBU62aibqPWxIyLV8HQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>人工智能很可能在不久的将来成为制药工业中一种无价的工具。]]></content:encoded><pubDate>Mon, 08 Mar 2021 06:11:07 +0800</pubDate></item><item><title>小药综述：COVID-19下火热的IO药物</title><link>https://mp.weixin.qq.com/s/h3Oo283ldZs0XR2jZI-s4A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFJwYKVxiaVpn9WVicapLJxSBIB5lZP8AfZ0I3hbo52sQSl9yxrpwYTtlErpW3oSy4lYdRSLfzUDRdQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>2020年COVID-19凶猛来袭，但肿瘤免疫药物的开发依然火热。]]></content:encoded><pubDate>Mon, 08 Mar 2021 06:11:07 +0800</pubDate></item><item><title>小药综述：肿瘤免疫中的小分子药物</title><link>https://mp.weixin.qq.com/s/msr63ZetfP-rplqJvf_94Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwTQEzQKmLAWfJia1LzgObsPZ5ibZIw7y0AdUR6e5BMAh34rTEWrrLpP8dNKicxzUN7nZRj4JUca8RIfg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>肿瘤免疫中的小分子药物有哪些独特优势？]]></content:encoded><pubDate>Mon, 08 Mar 2021 06:11:07 +0800</pubDate></item><item><title>小药谈双抗：挑战与开发策略</title><link>https://mp.weixin.qq.com/s/N0bYFNKxX57JNGwEzG57gg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFRGkQ07eOic0UBYaxXCrx9h5A8GtN4PiciauBY1NGicZpQokZMX3GeA1iag405fuKXadstf6jF3M2J2Zw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>新一代双特异性抗体抗肿瘤药物的挑战与开发策略]]></content:encoded><pubDate>Sun, 07 Mar 2021 06:14:09 +0800</pubDate></item><item><title>小药谈双抗：结构与功能优化</title><link>https://mp.weixin.qq.com/s/chE784-qcvyZzsnjUr3g6Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFRGkQ07eOic0UBYaxXCrx9hTRzh2iablVOQ7v1ofdl7txkQ95BwFKlQfEW70hybzBylPn176SGzUAw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>基于结构的设计优化双特异性抗体的功能]]></content:encoded><pubDate>Sun, 07 Mar 2021 06:14:09 +0800</pubDate></item><item><title>小药谈双抗：BiTEs和它的兄弟姐妹</title><link>https://mp.weixin.qq.com/s/bGRa-ueVuVZWoFBkbPMAAQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwSyj3caSvOzuiaw1LcSUBaeO0bichibRicIDQ4u7xTtZC147Jfre2w9iaBSwsqlQ4QpyQoeOVia7p4kbDAA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>曾惊艳了世人的BiTEs，后续开发是否依然值得期待？]]></content:encoded><pubDate>Sun, 07 Mar 2021 06:14:09 +0800</pubDate></item><item><title>小药谈双抗：CD33靶向双抗</title><link>https://mp.weixin.qq.com/s/CRvviuBQRs1T69sXzyeLjg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/ibZVzbA7glfFRGkQ07eOic0UBYaxXCrx9h9icc25I1sX6N0v9mwCu234SVicAmaDNf41JHTLMBQbhExRqfHEzNKUGw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>CD33靶向双特异性抗体的开发现状]]></content:encoded><pubDate>Sun, 07 Mar 2021 06:14:09 +0800</pubDate></item></channel></rss>